[ET Net News Agency, 31 May 2024] Goldman Sachs raised the target price for CSPC Pharma
(01093) to HKD10.26 from HKD9.73 and maintained the "buy" rating.
The research house said the key downside risks are (1) earlier-than-expected VBP for
NBP; (2) slower-than-expected ramp-up of new products; (3) failure of major R&D projects;
and (4) greater-than-expected price cut impacts on generic drug sales. (rc)